<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical risk assignment and suggested therapies in childhood acute lymphoblastic leukemia</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical risk assignment and suggested therapies in childhood acute lymphoblastic leukemia</h1>
<div class="graphic"><div class="figure"><div class="ttl">Clinical risk assignment and suggested therapies in childhood acute lymphoblastic leukemia</div><div class="cntnt"><table cellspacing="0"><colgroup width="15%"></colgroup><colgroup width="40%"></colgroup><colgroup span="3" width="15%"></colgroup> <tbody> <tr> <td class="subtitle1">Risk group</td> <td class="subtitle1">Features</td> <td class="subtitle1">Percent</td> <td class="subtitle1">Recommended therapy</td> <td class="subtitle1">Projected five-year event-free survival</td> </tr> <tr class="divider_bottom"> <td>Low</td> <td> <p><strong>ALL</strong> of the following:</p> <ol> <li> <p>NCI standard risk group*</p> </li> <li> <p>Lesser risk cytogenetics: <br/> Trisomies 4 and 10<br/> <strong>or<br/> </strong>ETV-RUNX1 (United States)<br/> <strong>or</strong> <br/> Hyperdiploid (Europe)</p> </li> <li> <p>Rapid response to therapy<sup>¶</sup></p> </li> </ol> </td> <td>15%</td> <td>Conventional antimetabolite-based therapy</td> <td>&gt;95%</td> </tr> <tr class="divider_bottom"> <td>Average</td> <td> <p><strong>EITHER </strong>of the following:</p> <ol> <li> <p>NCI standard risk group*<br/> <strong>and<br/> </strong>Rapid response to therapy<sup>¶</sup></p> </li> <li> <p>NCI standard risk group*<br/> <strong>and<br/> </strong>Lesser risk cytogenetics<br/> <strong>and<br/> </strong>Slow response to therapy<sup>Δ</sup></p> </li> </ol> </td> <td>36%</td> <td>Intensified antimetabolite therapy</td> <td>90 to 95%</td> </tr> <tr class="divider_bottom"> <td>High</td> <td> <p><strong>ANY </strong>of the following:</p> <ol> <li> <p>NCI high risk group<sup>◊<br/> </sup><strong>and<br/> </strong>Rapid response to therapy<sup>¶</sup></p> </li> <li> <p>NCI standard risk group*<br/> <strong>and<br/> </strong>Slow response to therapy<sup>Δ§</sup></p> </li> <li> <p>CNS-positive leukemia</p> </li> <li> <p>Testicular leukemia</p> </li> </ol> </td> <td>25%</td> <td>Intensive multiagent chemotherapy</td> <td>88 to 90%</td> </tr> <tr class="divider_bottom"> <td>Very high</td> <td> <p><strong>ANY</strong> of the following:</p> <ol> <li> <p>MRD+ at day 29<sup>§</sup></p> </li> <li> <p>Induction failures</p> </li> <li> <p>MLL rearrangements <br/> <strong>or<br/> </strong>iAMP21 amplification</p> </li> <li> <p>Age &lt;1 year (or &gt;13 years if treated on a COG protocol)</p> </li> </ol> </td> <td>24%</td> <td> <p>Consider allogeneic hematopoietic cell transplantation in first remission</p> <p>Allogeneic transplant <strong>not</strong> recommended for infants</p> </td> <td>&lt;80%</td> </tr> <tr> <td rowspan="2">Special groups</td> <td> <p>T cell ALL</p> </td> <td> </td> <td> <p>Intensive multiagent chemotherapy</p> </td> <td> <p>66 to 80%<sup>[1,2]</sup></p> <p><sup></sup></p> </td> </tr> <tr> <td>  <p>Philadelphia chromosome<br/> [t(9;22)]</p> </td> <td> </td> <td>  <p>Intensive multiagent chemotherapy containing a BCR-ABL tyrosine kinase inhibitor</p> </td> <td>  <p>70%<sup>[3]</sup></p> </td> </tr> </tbody></table></div><div class="graphic_footnotes">WBC: white blood cell count; NCI: National Cancer Institute; MRD: measureable residual disease; CNS: central nervous system; MLL: mixed lineage leukemia gene; iAMP21: intrachromosomal amplification of chromosome 21; COG: Children's Oncology Group; ALL: acute lymphoblastic leukemia.<br/>* NCI standard risk group: WBC &lt;50,000/microL <strong>AND </strong>age one to &lt;10 years.<br/>¶ MRD negative at days 8 and 29 (rapid response to therapy).<br/>Δ MRD positive at day 8 and negative at day 29 (slow response to therapy).<br/>◊ NCI high risk group: WBC ≥50,000 microL <strong>OR</strong> age ≥10 years (up to 13 years if treated on a COG protocol).<br/>§ With some exceptions.<br/></div><div class="graphic_reference">References:<br/><ol>
<li>Dunsmore KP, Devidas M, Linda SB, et al. Pilot study of nelarabine in combination with intensive chemotherapy in high-risk T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. J Clin Oncol 2012; 30:2753.</li>
<li>Asselin BL, Devidas M, Wang C, et al. Effectiveness of high-dose methotrexate in T-cell lymphoblastic leukemia and advanced-stage lymphoblastic lymphoma: a randomized study by the Children's Oncology Group (POG 9404). Blood 2011; 118:874.</li>
<li>Schultz KR, Carroll A, Heerema NA, et al. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology group study AALL0031. Leukemia 2014; 28:1467.</li></ol></div><div id="graphicVersion">Graphic 71649 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
